Drugs / CART-EGFRvIII T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03726515 | Mar 2019 → Feb 2021 | glioblastoma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-EGFRvIII T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03726515 ↗ |
| Modality | Cell therapy | “autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular...” NCT03726515 ↗ |